Cargando…

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

Both genomic and transcriptomic signatures have been developed to predict responses of metastatic melanoma to immune checkpoint blockade (ICB) therapies; however, most of these signatures are derived from pre-treatment biopsy samples. Here, we build pathway-based super signatures in pre-treatment (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Kuang, Wei, Shiyou, Wei, Zhi, Frederick, Dennie T., Miao, Benchun, Moll, Tabea, Tian, Tian, Sugarman, Eric, Gabrilovich, Dmitry I., Sullivan, Ryan J., Liu, Lunxu, Flaherty, Keith T., Boland, Genevieve M., Herlyn, Meenhard, Zhang, Gao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519947/ https://www.ncbi.nlm.nih.gov/pubmed/34654806 http://dx.doi.org/10.1038/s41467-021-26299-4

Ejemplares similares

Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
por: Sahu, Avinash Das, et al.
Publicado: (2019)

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
por: Echevarría‐Vargas, Ileabett M, et al.
Publicado: (2018)

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
por: Shi, Alvin, et al.
Publicado: (2020)

What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
por: Cui, Ruichen, et al.
Publicado: (2022)

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance
por: Zhang, Jian, et al.
Publicado: (2022)

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
por: Bai, Xue, et al.
Publicado: (2021)

Tumor-Infiltrating PD-1(hi)CD8(+)-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
por: Yang, Zhenyu, et al.
Publicado: (2021)

Gene expression profiling of melanoma cells – searching the haystack
por: Brafford, Patricia, et al.
Publicado: (2005)

Narrowing the knowledge gaps for melanoma
por: Slipicevic, Ana, et al.
Publicado: (2012)

Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma
por: Bogenrieder, Thomas, et al.
Publicado: (2002)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype
por: Hao, Xue, et al.
Publicado: (2020)

Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity
por: Liu, Wei, et al.
Publicado: (2020)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

MITF Modulates Therapeutic Resistance through EGFR Signaling
por: Ji, Zhenyu, et al.
Publicado: (2015)

TRIM15 and CYLD regulate ERK activation via lysine 63-linked polyubiquitination
por: Zhu, Guixin, et al.
Publicado: (2021)

Feasibility and safety of robot-assisted thoracic surgery for lung lobectomy in patients with non-small cell lung cancer: a systematic review and meta-analysis
por: Wei, Shiyou, et al.
Publicado: (2017)

Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function
por: Leu, Julia I-Ju, et al.
Publicado: (2017)

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
por: Li, Ling, et al.
Publicado: (2011)

From cancer stem cells to tumor maintenance in melanoma
por: Fukunaga-Kalabis, Mizuho, et al.
Publicado: (2011)

Pre-clinical modeling of cutaneous melanoma
por: Rebecca, Vito W., et al.
Publicado: (2020)

Challenges in the humanized mouse model for cancer: A commentary
por: Ramirez-Salazar, Eric, et al.
Publicado: (2021)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
por: Fofaria, Neel M., et al.
Publicado: (2015)

BAP1 PLAYS A SURVIVAL ROLE IN CUTANEOUS MELANOMA
por: Kumar, Raj, et al.
Publicado: (2014)

Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growth
por: Caron, Jennifer M., et al.
Publicado: (2023)

Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants
por: Stopfer, Lauren E., et al.
Publicado: (2021)

Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions
por: Fukunaga-Kalabis, Mizuho, et al.
Publicado: (2008)

Autophagy Paradox: Strategizing Treatment Modality in Melanoma
por: Pangilinan, Christian, et al.
Publicado: (2023)

Resistance to checkpoint blockade therapy through inactivation of antigen presentation
por: Sade-Feldman, Moshe, et al.
Publicado: (2017)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
por: Liu, Zheng, et al.
Publicado: (2020)

Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma
por: Chen, Shuzhao, et al.
Publicado: (2022)

The macrophage: Switches from a passenger to a driver during anticancer therapy
por: Wang, Tao, et al.
Publicado: (2015)

HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8(+) T-cell infiltration into tumors
por: Guan, Lei, et al.
Publicado: (2022)

Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3′ untranslated region of TRIT1
por: Swoboda, Rolf K, et al.
Publicado: (2015)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
por: Kim, Hyungsoo, et al.
Publicado: (2015)

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness
por: Chen, Xiangyu, et al.
Publicado: (2023)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8i5rt9f6edre0ca65mpngl8fhu